Remarkably, a high tumor content of cytoplasmic peroxiredoxin 6 (PRX6) predicted better OS and DFS for lung cancer patients both by Kaplan-Meier estimates (Fig. 3b) and in univariate Cox regression analysis (Table 1), suggesting that the activation of the cytoplasmic antioxidant response protects from cancer progression. Here, PRDX6 is linked to lung cancer.